About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

HFpEF and 2-year Mortality of COPD Patients

NCT04277429·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Milan Sova, Ph.D.
CONTACT
588445326 [email protected]
Ondrej Zela, MD
CONTACT
[email protected]

Lead

University Hospital Olomouc

Age

40–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Exacerbation of chronic obstructive pulmonary disease requiring hospitalization
Age 40 - 80 years
Performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG)
Long acting beta agonist (LABA)/ long acting antimuscarinic (LAMA) bronchodilator treatment

You may not be if

Presence of major heart valve dysfunction
Documented noncompliance with treatment
Presence of active malignancy
Body mass index \> 40
Interstitial lung disease

The record

StatusUnknown

PhaseNo phase

Taking part150

StartedJul 2020

UpdatedNov 2, 2022

Conditions

Chronic Obstructive Pulmonary Disease Heart Failure

Where2

Frydek Mistek Hospital
Frýdek-Místek, Czechia
University Hospital Olomou
Olomouc, Czechia

Clareo Health | HFpEF and 2-year Mortality of COPD Patients